News for Axsome Therapeutics, Inc. (0HKF.L)

**media[651583]**

Axsome Therapeutics, under the ticker AXSM, has introduced SYMBRAVO, a new prescription medication available in the United States for the acute treatment of mig

Axsome Therapeutics (AXSM) receives continual support from HC Wainwright & Co., as the investment firm reiterates its Buy rating on the stock. The most recent a

Axsome Therapeutics launches SYMBRAVO for acute migraine treatment in the U.S. SYMBRAVO offers rapid pain relief within 2 hours, lasting

SYMBRAVO represents a novel multi-mechanistic approach to treating migraine that addresses multiple pathways underlying a migraine attack SYMBRAVO On My Side o

**media[650473]**

Axsome Therapeutics (AXSM) has encountered a hurdle with the U.S. Food and Drug Administration over its AXS-14 new drug application. The FDA's Division of Anest

Axsome Therapeutics (AXSM) faces a setback with the FDA's refusal to review its fibromyalgia drug application. Analysts predict a significant upside pot

Shares of Axsome Therapeutics, Inc. (AXSM) were losing around 4 percent in the pre-market trading on the Nasdaq after the firm Monday announced that it has received a Refusal to File or RTF letter from the U.

Key Highlights: Axsome Therapeutics (AXSM) receives an "Outperform" rating due to significant revenue potential from its antidepressant, Auvelity. Analys

Oppenheimer has commenced coverage on Axsome Therapeutics (AXSM), assigning it an Outperform rating and setting a price target at $185. According to analyst Mat

Summary Axsome Therapeutics Inc (AXSM), a pioneering biopharmaceutical company focused on central nervous system (CNS) disorders, announced on May 29, 2025, its

NEW YORK, May 29, 2025 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. ( AXSM), a biopharmaceutical company leading a new era in the treatment of central nervou

**media[638990]**

Axsome Therapeutics settles a patent dispute with Hetero Labs over Sunosi, paving the way for future generic competition. Analysts forecast significant upsi

Axsome Therapeutics (AXSM) has reached a settlement with Hetero Labs Ltd. and its affiliates, resolving a patent lawsuit regarding Axsome's SUNOSI product. The

NEW YORK, May 27, 2025 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. ( AXSM) (Axsome), a biopharmaceutical company leading a new era in the treatment of centr

SAN DIEGO, May 14, 2025 (GLOBE NEWSWIRE) -- Johnson Fistel, PLLP is investigating potential violations of federal and state laws by certain officers of the fo

H.C. Wainwright has adjusted its target price for Axsome Therapeutics (AXSM), reducing it to $180 from the previous $200, while maintaining a Buy rating on the